Neumora Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
Neumora Therapeutics, Inc. (NMRA)
Company Research
Source: GlobeNewswire
Announced class-leading data from diet-induced obesity (DIO) mouse model with NMRA-215, a potentially best-in-class, highly brain-penetrant, oral NLRP3 inhibitor, and expect to initiate Phase 1 study in first quarter of 2026 Advancing Phase 1 studies with two potentially best-in-class positive allosteric modulators (PAMs), NMRA-861 and NMRA-898, with comprehensive franchise update expected by mid-2026 On-track to report data from Phase 1b study of NMRA-511 in Alzheimer’s disease agitation around the end of the year $40 million in non-dilutive capital drawn from Neumora’s existing facility with K2 HealthVentures Strong financial position with $171.5 million in cash, cash equivalents and marketable securities expected to support operations into 2027 WATERTOWN, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA) a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms of action for a
Show less
Read more
Impact Snapshot
Event Time:
NMRA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NMRA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NMRA alerts
High impacting Neumora Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
NMRA
News
- Neumora Therapeutics (NASDAQ:NMRA) was upgraded by analysts at Royal Bank Of Canada from a "sector perform" rating to an "outperform" rating.MarketBeat
- Neumora Therapeutics (NASDAQ:NMRA) had its price target raised by analysts at Stifel Nicolaus from $2.00 to $3.00. They now have a "hold" rating on the stock.MarketBeat
- Neumora Therapeutics GAAP EPS of -$0.35 misses by $0.02 [Seeking Alpha]Seeking Alpha
- Neumora Therapeutics to Participate in Upcoming Conferences in NovemberGlobeNewswire
- Neumora Therapeutics (NASDAQ:NMRA) had its price target raised by analysts at Needham & Company LLC from $6.00 to $8.00. They now have a "buy" rating on the stock.MarketBeat
NMRA
Earnings
- 11/6/25 - Miss
NMRA
Sec Filings
- 11/21/25 - Form 8-K
- 11/12/25 - Form 144
- 11/6/25 - Form 10-Q
- NMRA's page on the SEC website